Overheard at targovax ’s KOL event: “The logistics behind engineering a CARTcell are much more complicated than engineering a virus” - Dr. Dmitriy Zamarin, cancer researcher immunotherapy
1 Like
Professor Daniel Palmer,
3 Likes
Targovax er involvert her?
Jepp
Mitt Trvxminne, som går tilbake til 2015, kan ikke huske en eneste presentasjon som selskapet har hatt hvor kursen har gått opp i etterkant av presentasjonen.
Jeg solgte hele lasset med en (mager)gevinst denne uken, spent på hvordan tingene utarter seg i neste uke. Heier på selskapet og dere selv om jeg er ute for tiden.
Tror dette er tiden man faktisk skal eie Targovax, skjer så utrolig mye spennende!
1 Like
Ja er det noen gang man skal eie TRVX er det nå.
1 Like
Targovax reports encouraging disease-free survival (DFS) data from TG01 trial in resected pancreatic cancer
16.1 months median DFS with TG01 and gemcitabine combination for all 32 patients
in the trial19.5 months DFS in 2nd cohort who received an optimized dosing regimen
94% of patients had mutant RAS specific adaptive immune activation
Oslo, Norway, 15 October 2018 - Targovax ASA (OSE: TRVX), a clinical stage
biotechnology company developing immune activators to target hard to treat solid
tumors, today announces the full data set from the 32-patient phase I/II
clinical trial evaluating TG01 in resected pancreatic cancer in combination with
standard of care chemotherapy (gemcitabine). Median DFS for all 32 patients in
the trial was 16.1 months, and 19.5 months for the 2nd patient cohort who
received an optimized dosing regimen. DFS was measured from time of surgery.
This DFS outcome is encouraging when compared to historical controls for
gemcitabine monotherapy, such as the ESPAC4 and PRODIGE trials, which reported a
median DFS of around 13 months in similar patient populations.The trial enrolled a total of 32 patients, split in two patient cohorts
receiving different dosing regimens. The 1st cohort (n=19) received most TG01
injections before and during chemotherapy, whereas the 2nd cohort (n=13)
received more injections after completing the chemotherapy regimen. This is
believed to be a more optimal dosing schedule for therapeutic cancer vaccines
such as TG01. In May 2018, encouraging two-year survival rate and median overall
survival (mOS) was reported for the 2nd patient cohort, and for all 32 patients
in the trial combined, see press
release (http://www.targovax.com/Investors/News/News-Details/2018/Targovax
-strengthens-2-year-survival-rate-in-resected-pancreatic-cancer-with-TG01
-/default.aspx).Summarizing the data from the trial published to date:
Full trial, 32 patients (both cohorts combined)
· 16.1 months median disease-free survival (mDFS)
· 33.4 months median overall survival (mOS)
· 72% of patients (23/32) were alive two years after surgery
· 94% of patients (30/32) demonstrated mutant RAS-specific immune activationFirst cohort, 19 patients
· 13.9 months median disease-free survival (mDFS)
· 33.1 months median overall survival (mOS)
· 68% of patients (13/19) were alive two years after surgerySecond cohort, 13 patients
· 19.5 months median disease-free survival (mDFS)
· Median overall survival not yet reached at time of analysis
· 77% of patients (10/13) were alive two years after surgeryThe full phase I/II data set will be presented by the trial Principal
Investigator, Professor Daniel Palmer from University of Liverpool in the UK, at
the Targovax capital markets update in Oslo, October 15th at 8:30am CET. The
presentation will also be available via webcast. Please see here for more
information (http://www.targovax.com/Investors/Events-and-Presentations/events
-and-webcasts/event-details/2018/Capital-Markets-Day/default.aspx).Dr. Magnus Jäderberg, CMO of Targovax, said: “We have previously reported strong
immune activation and signal of efficacy for TG01 in resected pancreatic cancer.
The median DFS data now presented further strengthens our confidence that TG01
provides a clinically meaningful benefit for this patient population, especially
when in the context of historical controls. The DFS benefit appears to be more
pronounced in the second cohort, which indicates that the post-chemo vaccination
schedule is an optimal dosing regimen that we should select in subsequent
development. It is also worth noting that median overall survival has not yet
been reached in the second patient cohort, and we will continue to track how
these patients perform with great interest”.About the study
CTTG01-01 is an open label phase I/II trial of TG01/GM-CSF in combination with
gemcitabine as adjuvant therapy for treating patients with resected
adenocarcinoma of the pancreas. The main objectives of the trail are an
assessment of safety and immune activation. The secondary objective is to assess
efficacy (disease-free survival and overall survival) at two years. The Company
has received consent to enable the reporting of overall survival for all
patients in the trial. The trial has been conducted in four centres in the UK
and Norway.The first cohort of 19 patients each received up to 36 injections of TG01/GM
-CSF, before, during and after six cycles of gemcitabine. The second cohort
consists of 13 patients, who received up to 15 injections of TG01/GM-CSF before
and after, but not during, gemcitabine treatment. The second cohort received on
average 7 injections after chemotherapy, compared to only one for the first
cohort. Overall, the treatment is well tolerated in both dosing regimens.
Although manageable, some allergic reactions were seen in patients in the first
cohort when treating with TG01 and gemcitabine in parallel. No such allergic
reactions were seen in the second cohort.TG01 is Targovax’s lead product candidate from its mutRAS neoantigen cancer
vaccine program. The product is an injectable peptide-based immunotherapy
designed to treat patients with mutant RAS solid tumors. RAS mutations are the
most frequently found oncogenic mutations in cancer overall, and are associated
with poor prognosis. Published data suggests that more than 90% of pancreatic
cancer patients have mutant RAS.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: [email protected]
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: [email protected]
Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: [email protected]
About TargovaxActivating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune
activators to target hard to treat solid tumors. Immuno-oncology is currently
one of the fastest growing therapeutic fields in medicine.Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect and
replicate in cancer cells. It is used as a therapeutic cancer vaccine and has
been shown to activate the immune system to generate tumor-specific immune
responses. In phase I trials, ONCOS-102 induced both local and systemic innate
and adaptive immune activation, which has been associated with clinical benefit.
ONCOS-102’s lead indication is mesothelioma, where the virus is currently being
tested in a randomized phase II trial, with a phase Ib safety lead-in cohort.
Another trial, in advanced melanoma, is expected to produce important proof of
concept data for checkpoint inhibitor refractory patients within the next 6-12
months.Targovax is also developing a neo-antigen cancer vaccine targeting tumors that
express mutated forms of RAS - mutations known to drive cancer. The TG vaccine
program has shown a signal of efficacy in a 32-patient trial with TG01 in
resected pancreatic cancer. A next generation product candidate, TG02 is
currently tested as monotherapy and will also be tested in combination with
Keytruda® (an anti-PD1 CheckEkstern link: http://www.newsweb.no/index.jsp?messageId=461225
Nyheten er levert av OBI.
http://www.netfonds.no/quotes/release.php?id=20181015.OBI.20181015S6
12 Likes
Show me the horizon!!
Gratulerer alle TRVX aksjonærer!
Dette vil bli en meeeget god dag for dere!
Gleder meg på deres vegne!!
Targovax har nå lagt frem data fra fase I/II-studien TG01 med 32 pasienter, opplyses det i en melding.
Median sykdomsfri overlevelse (DSF) var på 16,1 måneder, og 19,5 måneder for andre pasientkohort som mottok en optimalisert dosering. DFS ble målt fra pasientene ble operert.
Ifølge meldingen er DFS-resultatene oppmuntrende sammenlignet med historiske kontroller, som har rapportert en median DFS på rundt 13 måneder i lignende pasientpopulasjoner.
Første kohort, som hadde 19 deltakere, fikk mest TG01-injeksjoner før og under cellegift, mens andre kohort hadde 13 deltakere og og mottok flere injeksjoner etter fullført cellegift.
- Vi har i denne studien vist sterk immunaktivering og signal på klinisk effekt for TG01 i pasienter med operert kreft i bukspyttkjertelen. Lengden på både overlevelse og tiden det tok før pasientene fikk tilbakefall styrker vår tro på at TG01 kan bli et verdifullt behandlingsalternativ for denne pasientgruppen i framtiden, sier medisinsk direktør i Targovax, Magnus Jäderberg, i en kommentar.
Han trekker frem at selv om antallet pasienter er forholdsvis lavt, ser effekten på både overlevelse og tilbakefall ut til å være større i den andre kohorten. Han mener dette tyder på at vaksinasjon i etterkant av cellegift er viktig.
Targovax arrangerer kapitalmarkedsdag mandag. Se presentasjonen LIVE her fra kl. 08.30!
2 Likes
TRVX:16,1 MÅNEDER MEDIAN DFS MED TG01 OG GEMCITABINE
07:20
Oslo (TDN Direkt): Targovax annonserer fullstendige data fra TG01 fase I/II-studien med 32 pasienter. Median sykdomsfri overlevelse (DSF) for hele studien ble 16,1 måneder, og 19,5 måneder for andre pasientkohort som mottok en optimalisert dosering.
Det skriver selskapet i en melding mandag.
- Vi har i denne studien vist sterk immunaktivering og signal på klinisk effekt for TG01 i pasienter med operert bukspyttkjertelkreft. Nivået på både overlevelse og tiden det tok før pasientene fikk tilbakefall styrker vår tro på at TG01 kan bli et verdifullt behandlingsalternativ for denne pasientgruppen i framtiden, sier Magnus Jäderberg, medisinsk direktør i Targovax.
Første kohort hadde 19 deltakere og fikk mest TG01-injeksjoner før og under kjemoterapi, mens andre kohort hadde 13 deltakere og fikk mer injeksjoner etter fullført kjemoterapi.
- Selv om antallet pasienter er forholdsvis lavt, ser effekten på både overlevelse og tilbakefall ut til å være større i den andre kohorten. Dette tyder på at vaksinasjon etter kjemoterapi er viktig, noe som gir oss nyttig kunnskap for videre utvikling av TG programmet, sier Magnus Jäderberg.
DSF-resultatene er oppløftende sett i sammenligning med historiske behandlingsmetoder som ESPAC4 og PRODIGE-studier, som fikk median DSF på rundt 13 måneder med tilsvarende pasienter, skriver selskapet.
Studien fikk samlet:
16,1 måneder median sykdomsfri overlevelse
33,4 måneder median samlet overlevelse
72 prosent (23/32) var i live to år etter kirurgi
94 prosent (30/32) demonstrerte mutert RAS-spesifikk immunaktivering.
BNS, [email protected]
TDN Direkt, +47 21 95 60 70
Det spennende nå er hvordan sammenligningen blir mot folfirinox, der hvertfall Einarson / Radforsk var klar på at sistnevnte i hovedsak kun kan brukes på pasienter som er friske nok. Denne studien til trvx har ikke tatt hensyn til det og de nye dataene er betraktelig bedre enn Soc.
Og når mOS ennå ikke er nådd i kohort II så vil dataene bare bli bedre. Jeg er usedvanlig spent på hva selskapet nå tenker videre om TG01.
Det var da voldsomme sperrer som ligger ute å hindrer oppgang da!
Og Boff var de borte…
Varför gör man så om inte syftet är att få ner kursen?
Manipulasjon så det holder, da kursen gikk under 11.50 forsvant begge storpostene som lå ute.
Noen som klart ønsker å holde denne nede!
Siden CFO Torbjørn påpekte at analytikerne var tilstede idag forventer man vel noen oppdaterte analyser etter de siste aktiviteter?
3 Likes
Tilbake til fredagens sluttkurs. Så imponert ble markedet 